Artificial Intelligence has helped scientists reveal two distinct forms of prostate cancer which could revolutionise how the disease is diagnosed and treated in the future.
Children whose mothers have received antibiotic treatment during childbirth are more likely to develop autoimmune diseases compared to their counterparts, according to a recent registry-based study conducted at the University of Oulu, Finland, involving nearly 46,000 children. The most common autoimmune diseases in children include type 1 diabetes, celiac disease, and rheumatic diseases. However, the […]
A study by a scientific team from the University of Vienna and the MedUni Vienna, published in Cellular & Molecular Immunology [1], has a promising result from tumour research: The enzyme phosphoglycerate dehydrogenase (PHDGH) acts as a metabolic checkpoint in the function of tumour-associated macrophages (TAMs) and thus on tumour growth. Targeting PHGDH to modulate […]
Pulse oximeters – one of the most common medical devices used in global healthcare – can provide significantly overestimated oxygen saturation readings in people with darker skin tones, according to the most comprehensive study ever to explore the issue.
The mechanisms by which antidepressants and other emotion-focused medications work could be reconsidered due to an important new breakthrough in the understanding of how the gut communicates with the brain.
Ask someone what they think of when they hear the phrase “bile acids”, and you might get a few unpleasant answers.
Chronic liver disease is a serious global health problem that has a severe impact on personal quality of life. A major characteristic of chronic liver disease is liver fibrosis, where certain liver cells, called hepatic stellate cells, become activated and produce scar tissue that damages the liver. At present, no specific drugs are available to […]
A research project led by Lobelia Samavati, M.D., professor of internal medicine and molecular medicine and genetics at the Wayne State University School of Medicine, and supported by the National Institutes of Health (NIH), has developed a tool to rapidly and inexpensively diagnose sarcoidosis, a chronic inflammatory disease marked by the growth of tiny lumps […]
Novartis will acquire Calypso Biotech, a developer of Interleukin15 (IL-15) targeted therapies, for US$250 million plus a further $175 million based on the achievement of certain predetermined milestones.
Gilead Sciences will acquire CymaBay Therapeutics for US$4.3 billion. The acquisition will see Gilead add CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, to their existing liver therapy portfolio.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
